Choroidal Structural Changes Correlate With Neovascular Activity in Neovascular Age Related Macular Degeneration.

Purpose To correlate changes in choroidal thickness and vascularity index with disease activity in patients with neovascular age-related macular degeneration (nAMD). Methods Eyes diagnosed with AMD that had two sequential visits within 12 months and that had no choroidal neovascularization (CNV) or had inactive CNV at the first visit were included. Those that had active CNV at follow-up were enrolled as cases. Eyes that did not developed a CNV or that were still inactive at the second visit were enrolled as controls. Disease activity was based on optical coherence tomography (OCT) and fluorescein angiography findings. Subfoveal choroidal thickness (SCT), mean choroidal thickness (MCT), and choroidal vascularity index (CVI) were assessed on enhanced depth imaging OCT and compared between the baseline and follow-up visit. Subgroup analysis accounting for lesion type and previous treatment, if any, were performed. Results Sixty-five eyes from 60 patients (35 females) and 50 age- and sex-matched controls were included. At the active visit, cases had an increase from 164 ± 67 μm to 175 ± 70 μm in mean ± SD SCT and from 144 ± 45 μm to 152 ± 45 μm in MCT (both P < 0.0001). The mean CVI also increased at from 54.5% ± 3.3% to 55.4% ± 3.8% (P = 0.04). Controls did not show significant changes in choroidal measurements between the two visits. Mean SCT, MCT, and CVI values were similar for previously treated and treatment-naive eyes. Conclusions Choroidal thickness and CVI significantly increased with active disease in nAMD eyes. Changes in choroidal thickness may predict CNV development or recurrence before they are otherwise evident clinically.

[1]  A. Bill,et al.  Control of retinal and choroidal blood flow , 1990, Eye.

[2]  C. Delaey,et al.  Regulatory Mechanisms in the Retinal and Choroidal Circulation , 2000, Ophthalmic Research.

[3]  E. Steuer,et al.  Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration. , 2004, Ophthalmology.

[4]  R. Bhisitkul Vascular endothelial growth factor biology: clinical implications for ocular treatments , 2006, British Journal of Ophthalmology.

[5]  H. Koizumi,et al.  Choroidal circulatory disturbances associated with retinal angiomatous proliferation on indocyanine green angiography , 2008, Graefe's Archive for Clinical and Experimental Ophthalmology.

[6]  T. Desmettre,et al.  Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration , 2007, British Journal of Ophthalmology.

[7]  R. Spaide,et al.  A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. , 2009, American journal of ophthalmology.

[8]  J. Slakter,et al.  Enhanced depth imaging optical coherence tomography of the choroid in highly myopic eyes. , 2009, American journal of ophthalmology.

[9]  J. Marticorena,et al.  Retinal angiomatous proliferation. , 2011, Current drug targets.

[10]  I. Bhutto,et al.  Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex. , 2012, Molecular aspects of medicine.

[11]  Hideki Koizumi,et al.  Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. , 2012, Ophthalmology.

[12]  R. Schiffelers,et al.  Neovascular Age-Related Macular Degeneration , 2011, BioDrugs.

[13]  K. Nishida,et al.  Circadian changes in subfoveal choroidal thickness and the relationship with circulatory factors in healthy subjects. , 2012, Investigative ophthalmology & visual science.

[14]  S. Kinoshita,et al.  SUBFOVEAL CHOROIDAL THICKNESS IN RETINAL ANGIOMATOUS PROLIFERATION , 2014, Retina.

[15]  M. Ohji,et al.  Ranibizumab and Aflibercept: Intraocular Pharmacokinetics and Their Effects on Aqueous VEGF Level in Vitrectomized and Nonvitrectomized Macaque Eyes. , 2015, Investigative ophthalmology & visual science.

[16]  R. Kawasaki,et al.  Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration. , 2015, American journal of ophthalmology.

[17]  Soumya Jana,et al.  Automated estimation of choroidal thickness distribution and volume based on OCT images of posterior visual section , 2015, Comput. Medical Imaging Graph..

[18]  Seong Joon Ahn,et al.  Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization. , 2015, Investigative ophthalmology & visual science.

[19]  O. Strauß Pharmacology of the retinal pigment epithelium, the interface between retina and body system. , 2016, European journal of pharmacology.

[20]  R. Agrawal,et al.  CHOROIDAL VASCULARITY INDEX IN CENTRAL SEROUS CHORIORETINOPATHY , 2016, Retina.

[21]  Yong-Kyu Kim,et al.  CHOROIDAL THICKNESS CHANGE AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN RETINAL ANGIOMATOUS PROLIFERATION AND ITS RECURRENCE , 2016, Retina.

[22]  R. Agrawal,et al.  CHOROIDAL VASCULARITY INDEX: A Novel Optical Coherence Tomography Based Parameter in Patients With Exudative Age-Related Macular Degeneration , 2017, Retina.

[23]  R. Agrawal,et al.  Choroidal vascular changes in age‐related macular degeneration , 2017, Acta ophthalmologica.

[24]  R. Avery,et al.  SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB , 2017, Retina.